Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
PureTech Health PLC on Tuesday said its half-year loss narrowed, but saw its revenue fall by more than half.
In the six months to June 30, the Boston-based biotechnology company said revenue dropped by 54% to $3.2 million from $7.0 million the year before, reflecting a 59% decrease to £2.4 million in grant revenue due to the deconsolidation of its founded entity, Vedanta Biosciences, on March 31.
Pretax loss narrowed to $13.7 million from $56.3 million a year prior as research and development costs fell by 37% to $53.1 million. It also recorded a $61.8 million gain on deconsolidation of subsidiary, compared to $27.3 million the prior year.
Puretech did not declare an interim dividend, unchanged from a year ago.
Chief Executive Officer Daphne Zohar said: ‘Our unique model and disciplined execution have provided a safe harbour through the stormy market challenges, and while we can navigate in any environment, we are also very well-positioned to benefit if the tides potentially turn in favour of the biotech sector.’
Shares in Puretech were up 4.0% at 193.00 pence each in London on Tuesday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.